Skip to main content
letter
. 2017 Jan 2;102(3):e112–e114. doi: 10.3324/haematol.2016.160408

Figure 2.

Figure 2.

In vitro and clinical response to venetoclax. (A) Mononuclear cells were treated with 300nM of venetoclax for 24 hours. Cells were then stained with an anti-CD138-PE mAb. Plasma cell death was assessed by the loss of CD138 expression. Cell death percentage was calculated relative to control (ct) cells. FSC: forward scatter. (B) PR: partial response; VGPR: very good partial response.